On the contrary, in a phase I clinical trial (NCT00979862), cilengitide showed great efficacy and tolerance in recurrent GBM patients when combined with cediranib, a vascular endothelia growth factor (VEGF) inhibitor [41]. The gene discussed is VEGFA; the disease is glioblastoma.